eFFECTOR Therapeutics (EFTR) Competitors $0.0002 0.00 (0.00%) As of 09:45 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock EFTR vs. SMFL, AMPE, ONCSQ, PXMD, ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, and ACABWShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Smart for Life (SMFL), Ampio Pharmaceuticals (AMPE), OncoSec Medical (ONCSQ), PaxMedica (PXMD), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), and Atlantic Coastal Acquisition Corp. II (ACABW). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. Smart for Life Ampio Pharmaceuticals OncoSec Medical PaxMedica 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II eFFECTOR Therapeutics (NASDAQ:EFTR) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Is EFTR or SMFL more profitable? Company Net Margins Return on Equity Return on Assets eFFECTOR TherapeuticsN/A N/A N/A Smart for Life N/A N/A N/A Which has more volatility & risk, EFTR or SMFL? eFFECTOR Therapeutics has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Smart for Life has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Does the MarketBeat Community believe in EFTR or SMFL? eFFECTOR Therapeutics received 22 more outperform votes than Smart for Life when rated by MarketBeat users. However, 100.00% of users gave Smart for Life an outperform vote while only 79.31% of users gave eFFECTOR Therapeutics an outperform vote. CompanyUnderperformOutperformeFFECTOR TherapeuticsOutperform Votes2379.31% Underperform Votes620.69% Smart for LifeOutperform Votes1100.00% Underperform VotesNo Votes Do insiders and institutionals believe in EFTR or SMFL? 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 31.7% of Smart for Life shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better earnings & valuation, EFTR or SMFL? Smart for Life has higher revenue and earnings than eFFECTOR Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeFFECTOR Therapeutics$3.55M0.00-$35.81M-$13.080.00Smart for Life$11.11M0.00-$22.68MN/AN/A Does the media favor EFTR or SMFL? In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score. Company Overall Sentiment eFFECTOR Therapeutics Neutral Smart for Life Neutral SummarySmart for Life beats eFFECTOR Therapeutics on 6 of the 8 factors compared between the two stocks. Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart EFTR vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1,000.00$6.71B$5.49B$7.95BDividend YieldN/A3.05%5.11%4.22%P/E Ratio0.007.3522.6218.58Price / Sales0.00241.98397.85103.49Price / CashN/A65.8538.1834.62Price / Book0.006.496.744.25Net Income-$35.81M$143.41M$3.22B$248.18M7 Day PerformanceN/A2.24%1.59%1.36%1 Month PerformanceN/A7.16%4.09%3.85%1 Year PerformanceN/A-2.45%15.98%5.37% eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-100.0%$1,000.00$3.55M0.0010Gap UpSMFLSmart for LifeN/A$0.00+33.3%N/A-100.0%$3,000.00$11.11M0.00110Gap UpAMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.7%$2,000.00N/A0.0020ONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040PXMDPaxMedicaN/A$0.00flatN/A-100.0%$1,000.00N/A0.002ATNFW180 Life SciencesN/A$0.01flatN/A-11.8%$0.00N/A0.007News CoveragePositive NewsLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.02-4.5%N/AN/A$0.00N/A0.002Gap UpAIMDWAinosN/A$0.09+9.6%N/AN/A$0.00$20,729.000.0040Positive NewsALVOWAlvotechN/A$1.11-14.6%N/A-59.3%$0.00$489.68M0.004Short Interest ↑News CoverageGap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03flatN/A-76.3%$0.00N/A0.0015Gap Down Related Companies and Tools Related Companies Smart for Life Alternatives Ampio Pharmaceuticals Alternatives OncoSec Medical Alternatives PaxMedica Alternatives 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EFTR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
